Patents by Inventor James T. Palmer

James T. Palmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12018032
    Abstract: Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (I) including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include compound (I), as well as methods of using compound (I), alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: June 25, 2024
    Assignee: BIOMEA FUSION, INC.
    Inventors: Priyanka Somanath, Daniel Lu, Taisei Kinoshita, Brian Law, Thomas Butler, James T. Palmer, Nan-Horng Lin, Heow Meng Tan, Angelina Sau Man Wong, Siyi Jiang, Hongyan He
  • Publication number: 20240124428
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I): (I) wherein R1, R2, R3 and L are described herein.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 18, 2024
    Inventors: Phillip Albert COGHLAN, Alexandra Kalyna SUCHOWERSKA, James T. PALMER, James Anthony BONNAR, Benny EVISON
  • Publication number: 20240124467
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 18, 2024
    Inventors: Thomas Butler, James T. PALMER, Thorsten KIRSCHBERG, Nan-Homg LIN, Hon HUI, Ravindra UPASANI, Solomon B. UNGASHE, David SPERANDIO
  • Patent number: 11945785
    Abstract: Disclosed herein are heterocyclic compounds, for example, according to the following formula and analogs thereof: that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
    Type: Grant
    Filed: December 29, 2022
    Date of Patent: April 2, 2024
    Assignee: Biomea Fusion, Inc.
    Inventors: David Sperandio, Xiaodong Wang, Thorsten A. Kirschberg, James T. Palmer, Thomas Butler, Solomon B. Ungashe, Neil Howard Squires, Nan-Horng Lin, Ravindra B. Upasani, Amna Trinity-Turjuman Adam, Yongli Su, Thu Phan
  • Patent number: 11897868
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I): wherein A, D and Q are described herein.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: February 13, 2024
    Assignee: CARDIO THERAPEUTICS PTY LTD
    Inventors: Herbert Treutlein, Jun Zeng, Ian Dixon, Ian James, James T. Palmer
  • Publication number: 20230339867
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
    Type: Application
    Filed: December 29, 2022
    Publication date: October 26, 2023
    Inventors: David Sperandio, Xiaodong Wang, Thorsten A. Kirschberg, James T. Palmer, Thomas Butler, Solomon B. Ungashe, Neil Howard Squires, Nan-Horng Lin, Ravindra B. Upasani, Amna Trinity-Turjuman Adam, Yongli Su, Thu Phan
  • Publication number: 20230120115
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins for the treatment of diabetes mellitus. Also described are specific covalent inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the described compounds. Methods of using the menin-MLL covalent inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes mellitus.
    Type: Application
    Filed: August 10, 2022
    Publication date: April 20, 2023
    Inventors: Thomas BUTLER, James T. PALMER
  • Publication number: 20230086137
    Abstract: Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: August 10, 2022
    Publication date: March 23, 2023
    Inventors: Priaynka SOMANATH, Daniel LU, Taisei KINOSHITA, Brian LAW, Thomas BUTLER, James T. PALMER, Nan-Horng LIN, Heow Meng TAN, Angelina Sau Man WONG, Siyi JAING, Hongyan HE
  • Publication number: 20220002271
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I): wherein A, D and Q are described herein.
    Type: Application
    Filed: June 30, 2021
    Publication date: January 6, 2022
    Inventors: Herbert TREUTLEIN, Jun ZENG, Ian DIXON, Ian JAMES, James T. PALMER
  • Patent number: 11147797
    Abstract: The invention provides photodynamic therapeutic compounds and photodynamic methods of treatment. The photodynamic therapeutic compounds may be activated by long wavelength light. The photo-activation by long wavelength light may allow improved tissue penetration. The compounds are selected from the group consisting of compounds of formula (i), or a pharmaceutically acceptable salt thereof: formula (i) wherein PDC is a photodynamic core and wherein R1; R2; R3; and R4 are H, phenyl, pyridine-4-yl, methylpyridinium, N-methylpyridinium-3-yl; 2-phenyl-N-methylpyridinium-4-yl, 3-phenyl-N-methylpyridinium-4-yl, 4-phenyl-N-methylpyridinium-4-yl, 2-phenyl-N-methylpyridinium-3-yl, 3-phenyl-N-methylpyridinium-3-yl or 4-phenyl-N-methylpyridinium-3-yl; and wherein any one or more of R1, R2, R3 and R4 may be optionally substituted.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: October 19, 2021
    Assignee: SALT AND LIGHT PHARMACEUTICALS PTY. LTD.
    Inventors: Jun Zeng, Xinyu Tang, James T Palmer
  • Patent number: 11091466
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include comprising of Formula (I): (I) wherein A, D and Q are described herein.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: August 17, 2021
    Assignee: CARDIO THERAPEUTICS PTY LTD
    Inventors: Herbert Treutlein, Jun Zeng, Ian Dixon, Ian James, James T. Palmer
  • Publication number: 20200207743
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include comprising of Formula (I): (I) wherein A, D and Q are described herein.
    Type: Application
    Filed: May 16, 2018
    Publication date: July 2, 2020
    Inventors: Herbert TREUTLEIN, Jun ZENG, Ian DIXON, Ian JAMES, James T. PALMER
  • Publication number: 20190307725
    Abstract: The invention provides photodynamic therapeutic compounds and photodynamic methods of treatment. The photodynamic therapeutic compounds may be activated by long wavelength light. The photo-activation by long wavelength light may allow improved tissue penetration. The compounds are selected from the group consisting of compounds of formula (i), or a pharmaceutically acceptable salt thereof: formula (i) wherein PDC is a photodynamic core and wherein R1; R2; R3; and R4 are H, phenyl, pyridine-4-yl, methylpyridinium, N-methylpyridinium-3-yl; 2-phenyl-N-methylpyridinium-4-yl, 3-phenyl-N-methylpyridinium-4-yl, 4-phenyl-N-methylpyridinium-4-yl, 2-phenyl-N-methylpyridinium-3-yl, 3-phenyl-N-methylpyridinium-3-yl or 4-phenyl-N-methylpyridinium-3-yl; and wherein any one or more of R1, R2, R3 and R4 may be optionally substituted.
    Type: Application
    Filed: December 5, 2017
    Publication date: October 10, 2019
    Inventors: Jun ZENG, Xinyu TANG, James T Palmer
  • Publication number: 20170305943
    Abstract: Compounds and methods are provided for treating bacterial infections.
    Type: Application
    Filed: May 21, 2015
    Publication date: October 26, 2017
    Applicant: TAXIS Pharmaceuticals, Inc.
    Inventors: David Ryall Brown, Ian Collins, Lloyd George Czaplewski, David John Haydon, Penelope Anne Mayes, Jeffrey Peter Mitchell, James T Palmer, Neil Robert Stokes
  • Publication number: 20170260178
    Abstract: The present invention provides a compound of the following formula, salts, racemates, diastereomers, enantiomers, esters, carbamates, phosphates, sulfates, deuterated forms and prodrugs thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.
    Type: Application
    Filed: March 27, 2017
    Publication date: September 14, 2017
    Inventors: Christopher James Lunniss, James T. Palmer, Gary Robert William Pitt, Lorraine Claire Axford, David Davies
  • Patent number: 9651520
    Abstract: A capillary electrophoresis system which provides a microfluidic chip for capillary electrophoresis and a microfluidic interface module which fluidicly couples the microfluidic chip to external fluid sources and or external repositories.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: May 16, 2017
    Assignee: Mettler-Toledo Thornton, Inc.
    Inventors: Philippe M. Dekleva, Jonathan A. Vickers, James T. Palmer
  • Patent number: 9604976
    Abstract: The present invention provides a compound of the following formula, salts, racemates, diastereomers, enantiomers, esters, carbamates, phosphates, sulfates, deuterated forms and prodrugs thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: March 28, 2017
    Assignee: SPERO GYRASE, INC.
    Inventors: Christopher James Lunniss, James T. Palmer, Gary Robert William Pitt, Lorraine Claire Axford, David Davies
  • Publication number: 20170007615
    Abstract: The present disclosure relates to a novel combination of compounds, their use as antibacterials, compositions comprising them and methods for treating or preventing bacterial infections, more particularly, bacterial infections caused by Gram-negative pathogens and/or drug resistant Gram-negative bacteria.
    Type: Application
    Filed: February 3, 2015
    Publication date: January 12, 2017
    Inventors: Ian Collins, David John Haydon, Helena Thomaides-Brears, James T Palmer, Christopher James Lunniss
  • Patent number: 9511073
    Abstract: The present invention provides compounds of Formula (I): and salts, racemates, isomers, diastereoisomers, enantiomers, hydrates, solvates, N-oxides, pharmaceutically acceptable derivatives or prodrugs thereof. Also provided the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: December 6, 2016
    Assignee: TAXIS Pharmaceuticals, Inc.
    Inventors: David John Haydon, Lloyd George Czaplewski, Neil Robert Stokes, David Davies, Ian Collins, James T. Palmer, Jeffrey Peter Mitchell, Gary Robert William Pitt, Daniel Offermann
  • Publication number: 20150329530
    Abstract: The present invention provides a compound of the following formula, salts, racemates, diastereomers, enantiomers, esters, carbamates, phosphates, sulfates, deuterated forms and prodrugs thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.
    Type: Application
    Filed: March 21, 2013
    Publication date: November 19, 2015
    Inventors: Christopher James LUNNISS, James T. PALMER, Gary Robert William PITT, Lorraine Claire AXFORD, David DAVIES